These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10805060)

  • 1. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics.
    Mamiya K; Hadama A; Yukawa E; Ieiri I; Otsubo K; Ninomiya H; Tashiro N; Higuchi S
    Eur J Clin Pharmacol; 2000; 55(11-12):821-5. PubMed ID: 10805060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.
    Yukawa E; Mamiya K
    J Clin Pharm Ther; 2006 Jun; 31(3):275-82. PubMed ID: 16789993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism.
    Hadama A; Ieiri I; Morita T; Kimura M; Urae A; Irie S; Kaneda T; Mamiya K; Tashiro N; Higuchi S; Otsubo K
    Ther Drug Monit; 2001 Apr; 23(2):115-8. PubMed ID: 11294510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.
    Hung CC; Lin CJ; Chen CC; Chang CJ; Liou HH
    Ther Drug Monit; 2004 Oct; 26(5):534-40. PubMed ID: 15385837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between phenytoin pharmacokinetics and the CYP2C19 genotype in Japanese epileptic patients.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1998; 21(2):122-6. PubMed ID: 9579299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
    Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
    Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
    Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Hashimoto Y; Otsuki Y; Odani A; Takano M; Hattori H; Furusho K; Iui K
    Biol Pharm Bull; 1996 Aug; 19(8):1103-5. PubMed ID: 8874828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures.
    Lee SM; Chung JY; Lee YM; Park MS; Namgung R; Park KI; Lee C
    Arch Dis Child; 2012 Jun; 97(6):569-72. PubMed ID: 22331680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
    Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
    Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
    Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
    Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.